Compare Direxion Daily Semiconductor Bull 3X Shares (SOXL) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily Semiconductor Bull 3X Shares vs Stryker Corporation — how do they compare? Direxion Daily Semiconductor Bull 3X Shares trades at $139.76 (market cap $24.42B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 4.4× Direxion Daily Semiconductor Bull 3X Shares's market cap, and Stryker Corporation pays a 1.27% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bull 3X Shares for 15 Days and Stryker Corporation for 21 Days on average.
| SOXL | SYK | |
|---|---|---|
Market Cap | $24.42B | $106.24B |
Volume | 100,232,380 | 2,982,001 |
Sector | Leveraged / Inverse | Health |
52-Week High | $300.77 | $388.35 |
52-Week Low | $30.81 | $269.75 |
Typical Hold Time | 15 Days | 21 Days |
Enterprise Value | — | $117.70B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SOXL, the Direxion Daily Semiconductor Bull 3X ETF, is trading at $142.52, down 10.31% with a bearish technical signal. The semiconductor sector faces volatility, with mixed news including recent chip stock rallies and concerns about AI funding and regulatory tariffs. Technical indicators show neutral oscillators but bearish overall momentum, with key support at $134 and resistance at $153.
Outlook remains cautious due to leveraged ETF risks and semiconductor sector volatility. Investment opportunity exists for bullish semiconductor bets amid strong AI demand, but risks include high leverage decay, regulatory headwinds, and crowded trading positioning. Timing is critical given recent sharp rebounds and potential near-term drawdowns.
Stryker (SYK) trades at $276.97, up 0.57% today, amid a bearish technical signal with key support at $274 and resistance at $279. The company reported strong profitability with a 14.43% net income margin and beat Q2 2026 EPS estimates, though it missed in Q1. Recent news highlights ongoing legal scrutiny related to manufacturing issues disclosed in September 2026, which caused a significant share price drop.
Analyst consensus remains strongly bullish with a $368.11 price target, but risks include persistent manufacturing problems and potential securities litigation. Earnings growth and margin expansion support the long-term outlook, though near-term volatility may persist pending Q3 2026 results on October 29, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
